InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient ...
Patients with end-stage kidney disease who have spent years on transplant waitlists now face a new clinical reality: two ...
mRNA vaccines represent a transformative advance in vaccinology, combining rapid development timelines, scalable manufacturing, and strong immunogenicity with a favourable safety profile. Global ...
The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...